Related Experiment Videos
Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma
R C Leonard1, G E Smart, J R Livingstone
1Department of Clinical Oncology, Western General Hospital, Edinburgh, Scotland, UK.
Cancer Chemotherapy and Pharmacology
|January 1, 1989
Summary
This study compared combination chemotherapy to single-agent prednimustine for advanced ovarian cancer. Both treatments showed similar survival, but prednimustine offered durable responses with minimal toxicity.
Area of Science:
- Oncology
- Gynecologic Oncology
- Clinical Pharmacology
Background:
- Advanced epithelial ovarian carcinoma presents a significant treatment challenge.
- Optimizing chemotherapy regimens is crucial for improving patient outcomes.
Purpose of the Study:
- To compare the efficacy and toxicity of a combination chemotherapy regimen versus prednimustine alone in advanced ovarian cancer.
- To evaluate the impact of initial surgery extent on survival in different treatment arms.
Main Methods:
- Randomized trial involving 76 patients with advanced epithelial ovarian carcinoma.
- Treatment arms: hexamethylmelamine, 5-fluorouracil, cisplatin, and prednimustine vs. prednimustine alone for 6 months.
- Pathological confirmation of response rates and overall survival assessment.
Main Results:
- Response rates were 35% for combination chemotherapy and 28% for prednimustine.
- Overall survival was identical between the two groups.
- Seven patients achieved complete response; five remained disease-free for a median of 23 months.
- Initial surgery extent impacted survival in the prednimustine group but not the combination group.
Conclusions:
- Prednimustine monotherapy can achieve durable responses in advanced ovarian cancer with negligible toxicity.
- Combination chemotherapy did not demonstrate superior overall survival compared to prednimustine alone.
- Further research into optimal surgical management and prednimustine-based regimens is warranted.